Zobrazeno 1 - 10
of 42
pro vyhledávání: '"E. Rubio-Romero"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
D. Prieto-Peña, J. Loricera, S. Castañeda, C. Moriano, P. Bernabéu, P. Vela-Casasempere, J. Narváez, V. Aldasoro, O. Maíz, C. Fernández-López, M. Freire González, R. Melero, I. Villa-Blanco, B. González-Alvarez, R. Solans-Laqué, J. L. Callejas-Rubio, C. Fernández-Díaz, E. Rubio Romero, S. García Morillo, M. Minguez, C. Fernández-Carballido, E. De Miguel, J. Sanchez-Martin, E. Fernández, S. Melchor, E. Salgado-Pérez, B. Bravo, S. Romero-Yuste, E. Galíndez-Agirregoikoa, F. Sivera, I. Ferraz-Amaro, C. Hidalgo, C. Romero-Gómez, C. Galisteo, P. Moya, N. Alvarez-Rivas, J. Mendizabal, J. C. Nieto González, J. R. De Dios, J. L. Andreu, I. Pérez de Pedro, M. Revenga, J. L. Alonso Valdivieso, R. M. Rosa, I. De la Morena, N. Fernández-Llanio, E. Labrador, J. A. Roman-Ivorra, F. Ortiz-Sanjuán, A. García-Valle, A. Gallego, C. Iñiguez, N. Garrido-Puñal, R. De la Torre, R. López-González, P. Collado, E. Raya, F. Navarro, A. J. Mas, C. Ordás, M. D. Boquet, M. L. Velloso Feijoo, C. Campos Fernández, I. Rúa-Figueroa, A. Conesa, S. Manrique Arija, M. A. González-Gay, R. Blanco
Publikováno v:
Annals of the Rheumatic Diseases. 81:691-692
BackgroundTocilizumab (TCZ) has shown to be effective for large vessel vasculitis including giant cell arteritis (GCA) and Takayasu arteritis (TAK) (1-5). However, LVV-GCA and TAK show different demographic and clinical features that may influence on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d8036ee0db76d628f26719c124c11e29
https://doi.org/10.1136/annrheumdis-2022-eular.2330
https://doi.org/10.1136/annrheumdis-2022-eular.2330
Autor:
D. Prieto-Peña, F. Genre, S. Remuzgo Martinez, V. Pulito-Cueto, B. Atienza-Mateo, B. Sevilla, J. Llorca, N. Ortego, M. Leonardo, A. Peñalba, L. Martín-Penagos, J. A. Miranda Fillloy, J. Narváez, L. Caminal Montero, P. Collado, A. Fernandez-Nebro, G. Díaz-Cordoves, S. Cigarrán, J. Calviño, C. Cobelo, D. De Argila, E. F. Vicente-Rabaneda, E. Rubio-Romero, M. Leon Luque, J. M. Blanco-Madrigal, E. Galíndez-Agirregoikoa, O. Gualillo, J. Martin Ibanez, S. Castañeda, R. Blanco, M. A. González-Gay, R. López-Mejías
Publikováno v:
Annals of the Rheumatic Diseases. 81:1203-1204
BackgroundIgA vasculitis (IgAV) and IgA nephropathy (IgAN) are inflammatory conditions [1, 2], that share pathogenic mechanisms [1], in which B-lymphocytes are described as key cells implicated in these processes. BAFF, APRIL and BAFF-R are cytokines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f674d06448dcc702be9c5e26c1432a8b
https://doi.org/10.1136/annrheumdis-2022-eular.425
https://doi.org/10.1136/annrheumdis-2022-eular.425
Publikováno v:
Annals of the Rheumatic Diseases. 81:478.1-478
BackgroundUpadacitinib is a JAK inhibitor recently approved for rheumatoid arthritis treatment with promising results in its studies for severe moderate RA for which conventional therapies failed.ObjectivesTo study and describe the evolution of patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::accffe84836add840a844a14528c9872
https://doi.org/10.1136/annrheumdis-2022-eular.4879
https://doi.org/10.1136/annrheumdis-2022-eular.4879
Autor:
E. Galíndez-Agirregoikoa, D. Prieto-Peña, B. Joven-Ibáñez, E. Rubio Romero, O. Rusinovich, J. M. Belzunegui Otano, R. Melero, C. Ventín-Rodríguez, V. Jovani, R. Almodovar González, R. Garcia-Vicuna, T. González, I. Calvo, M. L. García-Vivar, S. Perez Barrio, I. Gorostiza, M. A. González-Gay, R. Blanco
Publikováno v:
Annals of the Rheumatic Diseases. 81:1583.1-1583
BackgroundUpadacitinib (UPA) is an inhibitor of JAK kinases recently approved by EMA for the treatment of psoriatic arthritis (PsA) in Europe (January 2021) 1. UPA has shown efficacy in refractory patients to anti-TNF 2.ObjectivesA) to assess efficac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c5189486997faf4f38f17cf719ff31c
https://doi.org/10.1136/annrheumdis-2022-eular.3263
https://doi.org/10.1136/annrheumdis-2022-eular.3263
Autor:
D. Prieto-Peña, S. Remuzgo Martinez, F. Genre, V. Pulito-Cueto, B. Atienza-Mateo, B. Sevilla, J. Llorca, N. Ortego, M. Leonardo, A. Peñalba, L. Martín-Penagos, J. A. Miranda Fillloy, J. Narváez, L. Caminal Montero, P. Collado, A. Fernandez-Nebro, G. Díaz-Cordoves, S. Cigarrán, J. Calviño, C. Cobelo, P. Quiroga Colino, J. Sanchez Perez, E. Rubio-Romero, M. Leon Luque, J. M. Blanco-Madrigal, E. Galíndez-Agirregoikoa, O. Gualillo, J. Martin Ibanez, S. Castañeda, R. Blanco, M. A. González-Gay, R. López-Mejías
Publikováno v:
Annals of the Rheumatic Diseases. 81:1201.2-1203
BackgroundIgA vasculitis (IgAV) and IgA nephropathy (IgAN) are inflammatory conditions that share pathogenic and molecular mechanisms [1] and may represent different outcomes of a continuous spectrum of the disease [2]. Interleukin (IL)-33 is a cytok
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c924599607b368a091229124d3ba145e
https://doi.org/10.1136/annrheumdis-2022-eular.414
https://doi.org/10.1136/annrheumdis-2022-eular.414
Autor:
Ana Peñalba, M. A. González-Gay, Javier Llorca, Fernanda Genre, J. Martin Ibanez, Leticia Lera-Gómez, B. Sevilla, Santos Castañeda, José A. Miranda-Filloy, Eva Galindez, Javier Narváez, Belén Atienza-Mateo, Raquel López-Mejías, María Teresa Leonardo, E. Rubio-Romero, D. De Argila, J. Sanchez Perez, P. Collado, J. M. Blanco-Madrigal, L. Caminal Montero, M. Leon Luque, S. Remuzgo Martinez, Norberto Ortego, Verónica Pulito-Cueto, Diana Prieto-Peña, Roman Blanco, L. Martín-Penagos
Publikováno v:
Annals of the Rheumatic Diseases. 80:267.2-268
Background:BAFF, APRIL and BAFFR are genes that encode cytokines with a key role in the development and survival of B-lymphocytes [1-4]: The B cell-activating factor (BAFF, also known as BLyS), a proliferation-inducing ligand (APRIL) and BAFF recepto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e84c4481c4a8e8c41d252b11dcfa313c
https://doi.org/10.1136/annrheumdis-2021-eular.707
https://doi.org/10.1136/annrheumdis-2021-eular.707
Publikováno v:
Annals of the Rheumatic Diseases. 80:53.2-54
Background:Listeria monocytogenes is a gram-positive bacteria that cause the invasive disease listeriosis. Human clinical syndromes are infrequent, mostly appearing in immunosuppressed individuals, newborns, the elderly, pregnant women, and occasiona
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a150d48b958e6008bd20388086ec15a0
https://doi.org/10.1136/annrheumdis-2021-eular.4282
https://doi.org/10.1136/annrheumdis-2021-eular.4282
Autor:
C. Fernández-Díaz, S. García Morillo, C. Romero-Gómez, Raquel Rosa, Roman Blanco, M. Freire González, Cristina Fernández-Carballido, Norberto Ortego, Pilar Bernabeu, F.M. Ortiz Sanjuan, E. Rubio Romero, Carlos Fernández-López, N. Fernández-Llanio, M. J. Montesa, M. A. González-Gay, S. Castañeda, J. L. Alonso Valdivieso, B. González-Alvarez, J.A. Narváez, S. Manrique Arija, Juan Salvatierra, Susana Romero-Yuste, E. Salgado-Pérez, P. Vela-Casasempere, J. Mendizabal, B. Bravo, Diana Prieto-Peña, P. S. Laura, José-Luis Callejas-Rubio, Noelia Alvarez-Rivas, Belén Atienza-Mateo, Sheila Melchor, C. Hidalgo, I. Pérez de Pedro, E. De Miguel, Miguel Minguez, Javier Loricera, R. Gómez de la Torre, P. Moya, Roser Solans-Laqué, Santiago Rodríguez Suárez, M. Delgado Sanchez
Publikováno v:
Annals of the Rheumatic Diseases. 80:1208.2-1209
Background:Tocilizumab (TCZ) has shown to be effective for large vessel vasculitis including Takayasu arteritis (TAK) (1-3). Most evidence in TAK comes from Asian patients. However, white patients seem to have different clinical and prognostic featur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4116235435e46b602206fb405044c2e2
https://doi.org/10.1136/annrheumdis-2021-eular.1747
https://doi.org/10.1136/annrheumdis-2021-eular.1747
Autor:
P. Collado, Santos Castañeda, S. Cigarrán, D. De Argila, Diana Prieto-Peña, Javier Llorca, L. Caminal Montero, Eva Galindez, Ana Peñalba, Belén Atienza-Mateo, J. Sanchez Perez, Fernanda Genre, J. Martin Ibanez, J. M. Blanco-Madrigal, B. Sevilla, M. Leon Luque, Norberto Ortego, S. Remuzgo Martinez, Leticia Lera-Gómez, María Teresa Leonardo, G. Díaz-Cordoves, José A. Miranda-Filloy, Javier Narváez, Raquel López-Mejías, E. Rubio-Romero, Roman Blanco, L. Martín-Penagos, Verónica Pulito-Cueto, C. Cobelo, M. A. González-Gay, José J. Calvino, Antonio Fernández-Nebro
Publikováno v:
Annals of the Rheumatic Diseases. 80:1076.3-1077
Background:IgA vasculitis (IgAV) and IgA nephropathy (IgAN) are inflammatory conditions that share pathogenic and molecular mechanisms [1] and may represent different outcomes of a continuous spectrum of disease [2]. Interleukin (IL)17A has been iden
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df74024efc2361f6843d4d4091b1ecfc
https://doi.org/10.1136/annrheumdis-2021-eular.766
https://doi.org/10.1136/annrheumdis-2021-eular.766